Accès ouvert
2026
article
OpenAlex
John Hixson, Jerry J. Shih, Sharona Ben‐Haim, Robert Beach et autres
Neurona Therapeutics is investigating NRTX-1001 cell therapy in two open-label, multicenter Phase 1/2 trials for drug-resistant unilateral (NCT05135091) and bilateral (NCT06422923) mesial temporal lobe epilepsy (MTLE). GABAergic cortical interneurons from the medial ganglionic eminence (MGE) are promising therapeutic targets in developing novel …
us
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
John Hixson, Gautam Banik, Marina Bershteyn, Alessandro Bulfone et autres
The objective is to present the Phase 3 EPIC (EPIlepsy Cell Therapy) trial design evaluating NRTX-1001 cell therapy for the treatment of seizures due to drug-resistant mesial temporal lobe epilepsy (MTLE). GABAergic cortical interneurons from the medial ganglionic eminence (MGE) are critical …
us
(code pays fourni par la source)
2026
article
OpenAlex
Peter Warnke, Naoum P. Issa, Kevin Graber, Vivek Buch et autres
To present results from an ongoing open-label, multicenter Phase 1/2 trial (NCT06422923) evaluating NRTX-1001 cell therapy for the treatment of seizures due to bilateral drug-resistant mesial temporal lobe epilepsy (MTLE).
us
(code pays fourni par la source)
2026
article
OpenAlex
Manher A. Joshi, Gautam Banik, Marina Bershteyn, Alessandro Bulfone et autres
To present the Phase 3 EPIC (EPIlepsy Cell Therapy) trial design evaluating NRTX-1001 cell therapy for the treatment of seizures due to drug-resistant mesial temporal lobe epilepsy (MTLE).